Lupus Therapeutics Expands Peer-to-Peer Program to Boost Clinical Trial Diversity
Event summary
- Lupus Therapeutics is expanding its Patient Advocates for Lupus Studies (PALS) program to over 100 research sites across North America.
- The program aims to address disparities in clinical trial participation, with Black individuals representing 43% of lupus cases but only 14% of trial participants.
- PALS connects individuals interested in clinical research with trained patient advocates, increasing knowledge and interest in trials.
- The expansion will support three clinical trials and builds on the program's success since its launch in 2019.
The big picture
The expansion of the PALS program addresses a critical gap in lupus research, where underrepresented groups have lower participation in clinical trials. This initiative aligns with broader industry efforts to enhance diversity in clinical research, which is essential for developing more effective and personalized treatments. The program's success could set a precedent for similar initiatives in other therapeutic areas.
What we're watching
- Program Impact
- Whether the expanded PALS program can significantly increase participation among underrepresented groups in lupus clinical trials.
- Industry Adoption
- The pace at which other biopharmaceutical companies adopt similar peer-to-peer support models for clinical trials.
- Regulatory Influence
- How regulatory bodies may respond to initiatives aimed at improving diversity in clinical trial participation.
Related topics